FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023111056> ?p ?o ?g. }

• W2023111056 endingPage "1137" @default.
• W2023111056 startingPage "1127" @default.
• W2023111056 abstract "Purpose To investigate the patterns of local failure and the risk factors predictive of local failure and to establish the dose–response relationships influencing the probability of local control in patients with Stage I and II angiocentric T-cell or natural killer (NK)/T-cell lymphoma who were treated with radiotherapy (RT) alone. Methods and materials We retrospectively reviewed the data from 102 patients with Ann Arbor Stage I and II angiocentric T-cell or NK/T-cell lymphoma who underwent RT alone to a median dose of 45 Gy (range, 20–70 Gy) between 1976 and 1998. The patterns of local failure, risk factors predictive of local failure, dose–response relationships, and survival data were analyzed. Because of the protean feature of local recurrences, the sites of local failure were allocated to one of three categories: true recurrence (TR), marginal recurrence (MR), and elsewhere recurrence (ER). Results Despite a higher complete remission rate (72%) after RT, 60 patients experienced treatment failure, including local failure in 48 (47%), regional failure in 3 (3%), and systemic failure in 28 (27%). The patterns of local failure were TR in 42, MR in 3, and ER in 5 patients. The median time to recurrence for TR/MR was shorter than that for ER (1 month for TR/MR vs. 12 months for ER). Patients with TR/MR had a more unfavorable prognosis than those experiencing ER (2-year survival rate after salvage treatment: 6% for TR/MR vs. 80% for ER; p <0.01). The dose–response curve was sigmoid in shape within the range of 20–54 Gy, which followed the plateau at doses in excess of about 54 Gy. A positive correlation was observed in the dose–response curve for the probability of local control (p = 0.017, logistic regression analysis). The overall 5-year actuarial survival and local recurrence-free survival rate for all patients was 42% and 53%, respectively. Achievement of complete remission was the most statistically significant risk factor predictive of TR/MR and the most important prognostic factor. Conclusion Our data confirm that local failure remains the major obstacle for patients who receive RT alone and that achievement of complete remission is a particularly important determinant of treatment success. Although dose escalation up to >54 Gy cannot entirely reduce the incidence of TR/MR, we believe it is important to identify an appropriate subset of patients for whom an additional boost dose may be beneficial. Given the high rate of local failure, an investigational approach should be conducted to supplement RT using radiosensitizers or more effective chemotherapeutic agents in future trials." @default.
• W2023111056 created "2016-06-24" @default.
• W2023111056 creator A5001896186 @default.
• W2023111056 creator A5002350066 @default.
• W2023111056 creator A5040135194 @default.
• W2023111056 creator A5041100246 @default.
• W2023111056 creator A5043099056 @default.
• W2023111056 creator A5050119772 @default.
• W2023111056 creator A5062047757 @default.
• W2023111056 creator A5063719728 @default.
• W2023111056 date "2004-07-01" @default.
• W2023111056 modified "2023-09-27" @default.
• W2023111056 title "Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints" @default.
• W2023111056 cites W15966455 @default.
• W2023111056 cites W1599858297 @default.
• W2023111056 cites W1843358390 @default.
• W2023111056 cites W1892168086 @default.
• W2023111056 cites W1965526826 @default.
• W2023111056 cites W1972972039 @default.
• W2023111056 cites W1973568615 @default.
• W2023111056 cites W1974720011 @default.
• W2023111056 cites W1977136166 @default.
• W2023111056 cites W1979234199 @default.
• W2023111056 cites W1980304797 @default.
• W2023111056 cites W1985239180 @default.
• W2023111056 cites W1993919529 @default.
• W2023111056 cites W1999663037 @default.
• W2023111056 cites W2018375072 @default.
• W2023111056 cites W2022388117 @default.
• W2023111056 cites W2024868664 @default.
• W2023111056 cites W2026540048 @default.
• W2023111056 cites W2029983273 @default.
• W2023111056 cites W2033655498 @default.
• W2023111056 cites W2040524492 @default.
• W2023111056 cites W2042810582 @default.
• W2023111056 cites W2052658782 @default.
• W2023111056 cites W2058718821 @default.
• W2023111056 cites W2064347805 @default.
• W2023111056 cites W2072538588 @default.
• W2023111056 cites W2074287871 @default.
• W2023111056 cites W2087099073 @default.
• W2023111056 cites W2094331223 @default.
• W2023111056 cites W2107202569 @default.
• W2023111056 cites W2108673054 @default.
• W2023111056 cites W2117291755 @default.
• W2023111056 cites W2121040659 @default.
• W2023111056 cites W2140998439 @default.
• W2023111056 cites W2158108681 @default.
• W2023111056 cites W2266123463 @default.
• W2023111056 cites W2274420705 @default.
• W2023111056 cites W4243630134 @default.
• W2023111056 cites W4250150910 @default.
• W2023111056 doi "https://doi.org/10.1016/j.ijrobp.2003.12.006" @default.
• W2023111056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15234048" @default.
• W2023111056 hasPublicationYear "2004" @default.
• W2023111056 type Work @default.
• W2023111056 sameAs 2023111056 @default.
• W2023111056 citedByCount "95" @default.
• W2023111056 countsByYear W20231110562012 @default.
• W2023111056 countsByYear W20231110562013 @default.
• W2023111056 countsByYear W20231110562014 @default.
• W2023111056 countsByYear W20231110562015 @default.
• W2023111056 countsByYear W20231110562016 @default.
• W2023111056 countsByYear W20231110562017 @default.
• W2023111056 countsByYear W20231110562018 @default.
• W2023111056 countsByYear W20231110562019 @default.
• W2023111056 countsByYear W20231110562020 @default.
• W2023111056 countsByYear W20231110562021 @default.
• W2023111056 countsByYear W20231110562022 @default.
• W2023111056 countsByYear W20231110562023 @default.
• W2023111056 crossrefType "journal-article" @default.
• W2023111056 hasAuthorship W2023111056A5001896186 @default.
• W2023111056 hasAuthorship W2023111056A5002350066 @default.
• W2023111056 hasAuthorship W2023111056A5040135194 @default.
• W2023111056 hasAuthorship W2023111056A5041100246 @default.
• W2023111056 hasAuthorship W2023111056A5043099056 @default.
• W2023111056 hasAuthorship W2023111056A5050119772 @default.
• W2023111056 hasAuthorship W2023111056A5062047757 @default.
• W2023111056 hasAuthorship W2023111056A5063719728 @default.
• W2023111056 hasConcept C126322002 @default.
• W2023111056 hasConcept C141071460 @default.
• W2023111056 hasConcept C143998085 @default.
• W2023111056 hasConcept C146357865 @default.
• W2023111056 hasConcept C151730666 @default.
• W2023111056 hasConcept C2777589544 @default.
• W2023111056 hasConcept C2779338263 @default.
• W2023111056 hasConcept C509974204 @default.
• W2023111056 hasConcept C71924100 @default.
• W2023111056 hasConcept C86803240 @default.
• W2023111056 hasConcept C90924648 @default.
• W2023111056 hasConceptScore W2023111056C126322002 @default.
• W2023111056 hasConceptScore W2023111056C141071460 @default.
• W2023111056 hasConceptScore W2023111056C143998085 @default.
• W2023111056 hasConceptScore W2023111056C146357865 @default.
• W2023111056 hasConceptScore W2023111056C151730666 @default.
• W2023111056 hasConceptScore W2023111056C2777589544 @default.
• W2023111056 hasConceptScore W2023111056C2779338263 @default.
• W2023111056 hasConceptScore W2023111056C509974204 @default.

• next